Formulary E-News: Having trouble viewing this e-mail? Click here.  
Formulary E-News
January 14, 2011
Formulary
In this issue
�
 Generic competition
�
 New MRSA guidelines
�
 FDA OKs Abstral with REMS requirement
�
 24-day oral contraceptive regimens with a progestogen more effective
�
 Etravirine label update
 

Survey

This month we would like to know...

Egrifta (tesamorelin) was recently FDA-approved to treat HIV-associated lipodystrophy (aka, visceral adipose tissue [VAT]), which will be available this month. VAT has been associated with adverse cardiovascular outcomes. How is your health-system covering or planning on covering this injectable drug product?

1) We will be/are covering it as a medically necessary drug if patients meet criteria for use.
   
2) We will be/are covering it as a medically necessary drug for all HIV patients.
   
3) We will not be covering it at all since it is a cosmetic product.
   
4) We have not yet decided how to cover this product.
   

Vote in our survey, and see what other P&T committee members have to say.
Click here to vote

Contact Us
Click here to contact a Formulary editor.

Click here to contact a Formulary sales representative.

Click here to learn about direct mail, reprints and classifieds in Formulary.

Formulary
 Digital Edition

Click here to view the current edition.

Click here to subscribe.
 
Generic competition on the horizon as many pharmaceutical companies face patent expirations
The impact of generic drugs—which now account for more than 70% of all prescriptions dispensed in the United States—will continue to increase as some of the world�s most-prescribed products lose their patent protection in 2011 and begin facing generic competition. More...
IDSA establishes guidelines to treat MRSA infections
The Infectious Diseases Society of America is set to release its first guidelines for the treatment of the increasingly common and potentially deadly methicillin-resistant Staphylococcus aureus infection. More...
FDA approves Abstral with required REMS enrollment
FDA has approved fentanyl (Abstral, ProStraken) transmucosal tablets to manage breakthrough pain for adults with cancer. Fentanyl immediate-release transmucosal medications are administered on the soft surfaces of the mouth (inside of the cheek, gum, tongue), or the nasal passages or throat where they dissolve and are absorbed. More...
Longer oral contraceptive regimens containing a progestogen show higher effectiveness
Twenty-four-day oral contraceptive regimens containing a progestogen with a long half-life shows higher contraceptive effectiveness under routine medical conditions compared with conventional 21-day regimens, according to research published in the January 2011 issue of Obstetrics & Gynecology. More...
FDA OKs label update for etravirine
FDA has approved a label update to include a 200-mg formulation of etravirine (Intelence, Tibotec Therapeutics), a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 in adults resistant to an NNRTI and other antiretroviral agents. More...

Top 5 Web Stories:

 1. Focus on 2010: A year of novel pharmacologic agents in review

2. Focus on Azilsartan: A next-generation angiotensin II receptor blocker for the treatment of hypertension

3. Dabigatran etexilate (Pradaxa): An oral direct thrombin inhibitor

4. First-time generic approvals December 2010

5. Study finds acetaminophen increases blood pressure in patients with coronary artery disease

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.